Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New and Surprising Approach to Cancer Treatment: SENOTHERAPY

A New and Surprising Approach to Cancer Treatment: SENOTHERAPY

With each passing day, we encounter a new treatment approach in cancer. In May 2020, Nature published a study in which senotherapy, by "targeting dormant cells", prevented the proliferation of liver cancer cells in mouse models. This is the first study in hepatocellular carcinoma (liver cancer) to apply senotherapy.

Senotherapy targets dormant (non-dividing) cells using small-molecule inhibitors. Senotherapeutic properties are used in anti-aging approaches. The study investigated the applicability of senotherapy in liver cancers. For this purpose, the FB1 (fructose 1,6-bisphosphatase 1) gene in liver cells was analyzed. Loss of the FBP1 enzyme in human liver cells significantly increases tumor growth. Previous research has shown that FBP1 levels are low in stage 1 /early-stage) tumors and fall further as the disease progresses.

According to the Research Results

  • The FB1 enzyme was found to be present at low levels in hepatocellular carcinoma (HCC), the most common type of liver cancer.
  • Liver cancer was observed to progress rapidly in mice in which FBP1 enzyme activity was inhibited through genetic engineering. Liver tumor growth was also observed after loss of FB1 enzyme activity, independently of underlying factors such as obesity, alcoholism, and hepatitis.
  • The researchers succeeded in halting tumor progression by targeting these aged cells with senolytic drugs such as Navitoclax (a drug undergoing clinical trials for the treatment of hematologic malignancies), to prevent tumor progression caused by liver-cell-specific loss of FBP1.

What Does This Study Mean for Us?

  • This is the first genetic study to show that the BP1 enzyme is an important metabolic tumor suppressor in the liver. It was also discovered that abnormalities in the FB1 gene in liver cells affect the tumor microenvironment and thereby promote tumor growth.
  • Senotherapy has been shown to have potential benefits against liver cancer.
  • Senotherapy targets "non-cancerous and dormant" cells in the tumor microenvironment. These dormant cells have been found to promote the development of cancer.
  • Cells in the tumor microenvironment are also an important factor reducing the effectiveness of immunotherapies. Combining senotherapy and immunotherapy may offer an effective cancer treatment.

It must be emphasized that this study was carried out in a laboratory setting. These findings need to be confirmed through further clinical studies.

Related Topics:

- Aging cancer cells continue to survive by eating one another

- Why Does Treated Cancer Recur: Dormant Cancer Cells

- How Often Does Each Cancer RELAPSE (RECUR)?

Sources

Fuming Li et al.
FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome.
Nature Cell Biology, 4 May 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New and Surprising Approach to Cancer Treatment: SENOTHERAPY

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy